sr141716 has been researched along with Schizophrenia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giuffrida, A; Martinez, AA; Seillier, A | 1 |
| Abílio, VC; Almeida, V; Calzavara, MB; Crippa, JA; Hallak, JE; Levin, R; Peres, FF; Suiama, MA; Zuardi, AW | 1 |
| Piomelli, D | 1 |
| Kawohl, W; Roser, P; Vollenweider, FX | 1 |
| Ball, MP; Boggs, DL; Buchanan, RW; Conley, RR; Feldman, S; Gorelick, DA; Heishman, SJ; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Warren, KR; Wehring, HJ | 1 |
| Chong, HJ; Haussleiter, IS; Juckel, G; Kawohl, W; Maier, C; Norra, C; Roser, P | 1 |
| Boggs, DL; Buchanan, RW; Conley, RR; Gold, JM; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Waltz, J | 1 |
| Abílio, VC; Almeida, V; Calzavara, MB; Crippa, JA; da Silva, ND; Hallak, JE; Levin, R; Niigaki, ST; Peres, FF; Suiama, MA; Zuardi, AW | 1 |
| Ball, MP; Buchanan, RW; Conley, RR; Feldman, S; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Warren, KR | 1 |
| Garrick, T; Huang, XF; Zavitsanou, K | 1 |
| Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W | 1 |
| Bermudez-Silva, FJ; Bilbao, A; de Diego, Y; Fernandez-Espejo, E; Ferrer, B; Gornemann, I; Gorriti, MA; Moratalla, R; Navarro, M; Palomino, A; Rodríguez de Fonseca, F | 1 |
| Ballmaier, M; Bortolato, M; Gessa, G; Heinz, A; Rizzetti, C; Spano, P; Zoli, M | 1 |
1 review(s) available for sr141716 and Schizophrenia
| Article | Year |
|---|---|
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabidiol; Endocannabinoids; Humans; Memory; Piperidines; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-fos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Schizophrenia; Sensory Gating | 2010 |
5 trial(s) available for sr141716 and Schizophrenia
| Article | Year |
|---|---|
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Schizophrenia; Schizophrenic Psychology | 2011 |
Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Evoked Potentials, Auditory; Excitatory Amino Acid Antagonists; Humans; Ketamine; Male; Piperidines; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, N-Methyl-D-Aspartate; Rimonabant; Schizophrenia; Young Adult | 2011 |
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
Topics: Adolescent; Adult; Analysis of Variance; Cannabinoid Receptor Antagonists; Cognition Disorders; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Piperidines; Psychiatric Status Rating Scales; Pyrazoles; Rimonabant; Schizophrenia; Treatment Outcome; Young Adult | 2012 |
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Body Mass Index; Body Weight; Brain; Cannabinoid Receptor Antagonists; Double-Blind Method; Drug Inverse Agonism; Eating; Energy Intake; Female; Humans; Male; Middle Aged; Overweight; Pilot Projects; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Satiety Response; Schizophrenia; Schizophrenic Psychology; Signal Transduction; Treatment Outcome | 2013 |
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigational; Female; Haloperidol; Humans; Male; Middle Aged; Neurotensin; Peptide Fragments; Piperidines; Placebos; Psychotic Disorders; Pyrazoles; Pyrrolidonecarboxylic Acid; Receptors, Neurokinin-3; Research Design; Rimonabant; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2004 |
7 other study(ies) available for sr141716 and Schizophrenia
| Article | Year |
|---|---|
Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.
Topics: Amidohydrolases; Amygdala; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Carbamates; Cyclohexanols; Dose-Response Relationship, Drug; Endocannabinoids; Male; Phencyclidine; Piperidines; Polyunsaturated Alkamides; Prefrontal Cortex; Pyrazoles; Quinazolinones; Rats; Receptor, Cannabinoid, CB1; Receptor, Cholecystokinin B; Rimonabant; Schizophrenia; Social Behavior | 2013 |
Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain.
Topics: Analysis of Variance; Animals; Arachidonic Acids; Benzoxazines; Cannabinoid Receptor Modulators; Capsaicin; Disease Models, Animal; Dose-Response Relationship, Drug; Interpersonal Relations; Male; Morpholines; Motor Activity; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Rimonabant; Schizophrenia; Schizophrenic Psychology; TRPV Cation Channels | 2014 |
The element of surprise.
Topics: Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Delusions; Drug Administration Schedule; Humans; Lipogenesis; Mice; Mice, Knockout; Models, Biological; Nerve Endings; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Schizophrenia; Waist-Hip Ratio; Weight Loss | 2008 |
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
Topics: Animals; Cannabidiol; Cannabinoid Receptor Antagonists; Disease Models, Animal; Emotions; Male; Piperidines; Pyrazoles; Rats, Wistar; Rimonabant; Schizophrenia; Schizophrenic Psychology | 2012 |
Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.
Topics: Adult; Aged; Analysis of Variance; Autoradiography; Female; Gyrus Cinguli; Humans; Male; Middle Aged; Piperidines; Postmortem Changes; Pyrazoles; Radioligand Assay; Receptor, Cannabinoid, CB1; Rimonabant; Schizophrenia | 2004 |
Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Piperidines; Pyrazoles; Quinpirole; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Rimonabant; Schizophrenia; Schizophrenic Psychology; Stereotyped Behavior | 2007 |
Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Phencyclidine; Piperidines; Psychoses, Substance-Induced; Pyrazoles; Rats; Receptors, Cannabinoid; Reflex, Startle; Rimonabant; Schizophrenia; Sensation Disorders; Synaptic Transmission | 2007 |